Early Stage Life Science Investors Converge in Fenway Park

Wednesday, September 17th, 2014 – Fenway Park, Boston, MA

The Redefining Early Stage Investments (RESI) Conference is reinventing the way investors and entrepreneurs connect and share information. Early stage scientist-entrepreneurs looking to raise capital will converge at the historic Fenway Park on September 17th for a one day partnering conference. The life science investor landscape has changed; venture capital has left a void and there is a plethora of new entities entering the space with capital to allocate. RESI will be host to well over 100 active investors from the 10 categories that LSN tracks, including Family Offices, Venture Philanthropy, Institutional Alternative Investors, Corporate Venture Capital and more.

The conference will also have representation from next-generation technology transfer, licensing and funding experts, and a series of free workshops. We urge all of our members to take a look at the program, and to take some time out to reeducate them regarding the new landscape unfolding in the life science investor arena.

Registration and sponsorship information is available at www.resiconference.com

For any inquires please reach out:

Tom Crosby
Conference Manager

Life Science Nation (LSN)
9 Hamilton Place, Suite B
Boston, MA, 02108

Office: (617) 600-3074
Email: [email protected]

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.